Pharmacia & Upjohn Camptosar
Executive Summary
Supplemental application (sNDA 20-571/08) for irinotecan (CPT-11) for treatment of metastatic carcinoma of the colon or rectum will be reviewed by the Oncologic Drugs Advisory Committee Sept. 3 beginning at 8:00 a.m